



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/811,045	03/16/2001	Robert E. Scott	D6386D

**CONFIRMATION NO. 7993**

### FORMALITIES LETTER



\*OC000000006040174\*

Dr. Benjamin Adler  
Adler & Associates  
8011 Candle Lane  
Houston, TX 77071

Date Mailed: 05/04/2001

### NOTICE TO FILE CORRECTED APPLICATION PAPERS

#### *Filing Date Granted*

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
  - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- An Abstract not to exceed 150 words in length, commencing on a separate sheet (37 CFR 1.72(b)).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at

patin21help@uspto.gov or patin3help@uspto.gov

---

*Nyan*  
*A copy of this notice MUST be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**APPLICANT:** Scott, Robert E.

**§ ART UNIT:**

**FILED: March 16, 2001**

28

SERIAL NO.: 09/811,045

§

**FOR: cDNA Encoding P2P Proteins and Uses Of  
P2P cDNA Derived Antibodies and  
Antisense Reagents In Determining  
Proliferative Potential of Normal,  
Abnormal, and Cancer Cells in Animals  
and Humans**

**EXAMINER:**

**DOCKET:**  
**D6386/D**

Assistant Commissioner of Patents  
**ATTN: Customer Service Center**  
Washington, D.C. 20231

**RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS AND  
CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

Dear Sir:

In response to a Notice to File Corrected Application Papers mailed May 4, 2001 for the above-referenced patent application, Applicants submit herewith Figures 5 and 6 wherein the figures meet the margin requirements under 37 C.F.R. 1.84. Applicants further submit herewith a Sequence Listing, a computer readable form of the Sequence Listing, a Sequence Compliance Statement and a copy of the Formalities Letter. Please debit any fees that are due from Deposit Account No. 07-1185.

I hereby certify under 37 CFR 1.8 that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to: Customer Service Center, US Patent and Trademark Office, Washington, DC 20231. Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

DATE: June 8, 2001  
ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
713/270-5391  
BADLER1@houston.rr.com



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

~~RAD~~  
**APPLICANT:** Scott

## § ART UNIT:

**FILED:** March 16, 2001

10

SERIAL NO.: 09/811,045

**§ EXAMINER:**

**FOR: cDNA Encoding P2P Proteins And Use Of P2P  
cDNA-Derived Antibodies And Antisense  
Reagents In Determining The Proliferative  
Potential Of Normal, Abnormal And Cancer  
Cells In Animals And Humans**

DOCKET: D6386D

The Assistant Commissioner of Patents and Trademarks  
**BOX NON-FEE AMENDMENT**  
Washington, DC 20231

**COMPLIANCE OF REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Dear Sir:

Applicant hereby provides a computer readable form of the Sequence Listing on the enclosed 3.5 inch disk and a paper copy thereof for the above-referenced application. The disk is a 1.44 Mb IBM-formatted disk. The file is stored as D6386D/SEQ in text format. I hereby state that the content of the paper copy of the Sequence Listing filed as part of the above-captioned application and the enclosed computer readable copy of the Sequence Listing are the same.

Respectfully submitted,

Hijim den Adel

Benjamin Aaron Adler, Ph.D., J.D.  
Counsel for Applicant  
Registration No. 35,423

**ADLER & ASSOCIATES**  
8011 Candle Lane  
Houston, Texas 77071  
(713) 270-5391